ZTlido
Commercial- Indications
- Post-herpetic neuralgia
Company intelligence / Profile preview
Scilex has three FDA-approved non-opioid products on the market and several late-stage pipeline candidates. ZTlido® shows strong sales growth and international distribution deals. SP‑102 met primary and secondary endpoints in pivotal phase 3 trial. SP‑103 completed phase II with clear path to NDA after phase III; projected blockbuster potential. SP‑104 completed multiple phase I trials.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Scilex Pharmaceuticals.